Empowering the next generation of healthcare leaders

Empowering the next generation of healthcare leaders
attila_novartis

Empowering the next generation of healthcare leaders

Empowering the next generation of healthcare leaders
attila_novartis

Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

Giving voice to people with a misunderstood disease

Giving voice to people with a misunderstood disease
mihai_novartis

Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

Water project revives rural community in India

Water project revives rural community in India
mihai_novartis

A partnership against epilepsy

A partnership against epilepsy
tavasat1

A partnership against epilepsy

A partnership against epilepsy
tavasat1

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
arcticnovartis

  • In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs.
Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024

Novartis shares strategy and growth update at J.P. Morgan Healthcare Conference 2024
imberje1